文献速递乳腺癌

BRE12-158:新辅助化疗后残留三阴性乳腺癌的个体化治疗与医生选择治疗的随机II期试验

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
PubMed 文献 · J Clin Oncol · 2021-12-15

BRE12-158是一项II期多中心随机试验,2014年3月至2018年12月纳入193例新辅助化疗后残留三阴性乳腺癌患者,随机分配至基因组导向治疗(A组)或医生选择治疗(B组)。随机人群2年无病生存率A组56.6%(95%CI 0.45-0.70)vs B组62.4%(95%CI 0.52-0.75),无显著差异。结论:基因组导向治疗不优于医生选择治疗,卡培他滨应继续作为标准治疗。

要点

  • 新辅助化疗后残留三阴性乳腺癌患者中,基因组导向治疗与医生选择治疗的2年无病生存率无显著差异。
  • 随机人群2年无病生存率A组56.6%(95%CI 0.45-0.70)vs B组62.4%(95%CI 0.52-0.75)。
  • 卡培他滨应继续作为该人群的标准治疗,循环肿瘤DNA应被视为该领域试验的标准协变量。

核心结论

  • 对新辅助化疗后残留三阴性乳腺癌患者,基因组导向治疗不优于医生选择治疗。
  • 卡培他滨应继续作为标准治疗;然而其他药物在该背景下的活性为测试最佳联合方案以改善结局提供了依据。
  • 循环肿瘤DNA应被视为该背景下试验的标准协变量。

研究设计与样本

  • BRE12-158是一项II期多中心随机试验,于2014年3月至2018年12月入组193例新辅助化疗后残留三阴性乳腺癌患者。
  • 残留肿瘤采用二代测序检测进行测序,所有结果由分子肿瘤委员会裁定。
  • 患者随机分配至四周期基因组导向治疗(A组)或医生选择治疗(B组);无靶点患者被分配至B组。
  • 主要终点为随机分配患者的2年无病生存率;次要/探索性终点包括远处无病生存、总生存、毒性评估、治疗的时间演变和药物特异性结局。

主要发现

  • 193例患者被随机分配或被分配至B组。
  • 仅随机人群的估计2年无病生存率A组为56.6%(95%CI 0.45-0.70)vs B组为62.4%(95%CI 0.52-0.75)。
  • 在全体人群或随机人群中,无病生存、远处无病生存或总生存均未见差异。
  • 医生选择治疗中卡培他滨的使用随时间增加;随机分配较晚的患者远处复发较少。
  • 循环肿瘤DNA状态仍是结局的显著预测因素,部分患者在后新辅助治疗中显示清除。

临床怎么用

  • 作者结论认为卡培他滨应继续作为新辅助化疗后残留三阴性乳腺癌的标准治疗。
  • 作者认为其他药物在该背景下的活性为测试最佳联合方案以改善结局提供了依据。
  • 作者建议循环肿瘤DNA应被视为该背景下试验的标准协变量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy (NAC) have high risk of recurrence with prior data suggesting improved outcomes with capecitabine. Targeted agents have demonstrated activity across multiple cancer types. BRE12-158 was a phase II, multicenter trial that randomly allocated patients with TNBC with residual disease after NAC to genomically directed therapy versus treatment of physician choice (TPC). PATIENTS AND METHODS: From March 2014 to December 2018, 193 patients were enrolled. Residual tumors were sequenced using a next-generation sequencing test. A molecular tumor board adjudicated all results. Patients were randomly allocated to four cycles of genomically directed therapy (arm A) versus TPC (arm B). Patients without a target were assigned to arm B. Primary end point was 2-year disease-free survival (DFS) among randomly assigned patients. Secondary/exploratory end points included distant disease-free survival, overall survival, toxicity assessment, time-based evolution of therapy, and drug-specific outcomes. RESULTS: One hundred ninety-three patients were randomly allocated or were assigned to arm B. The estimated 2-year DFS for the randomized population only was 56.6% (95% CI, 0.45 to 0.70) for arm A versus 62.4% (95% CI, 0.52 to 0.75) for arm B. No difference was seen in DFS, distant disease-free survival, or overall survival for the entire or randomized populations. There was increased uptake of capecitabine for TPC over time. Patients randomly allocated later had less distant recurrences. Circulating tumor DNA status remained a significant predictor of outcome with some patients demonstrating clearance with postneoadjuvant therapy. CONCLUSION: Genomically directed therapy was not superior to TPC for patients with residual TNBC after NAC. Capecitabine should remain the standard of care; however, the activity of other agents in this setting provides rationale for testing optimal combinations to improve outcomes. Circulating tumor DNA should be considered a standard covariate for trials in this setting.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Schneider BP, Jiang G, Ballinger TJ, et al. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2021. PMID: 34910554. doi:10.1200/JCO.21.01657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。